Tokyo, June 13, 2017 – Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) announced that it have enterd into a collaboration research agreement with Numab Therapeutics AG (“Numab”) for the identification of a multispecific antibody candidate for development in inflammatory disease.
Under the agreement, Kaken will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program.
Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immuno-oncology and immunology, and has a number of discovery partnerships with pharmaceutical companies. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile. Numab is represented in Japan by PharmaBDL. For further information, visit www.numab.com